Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 22, 2023
Context: The Company entered into an inducement offer letter agreement with a holder of existing warrants to facilitate the exercise of those warrants at a reduced price in exchange for the issuance of new warrants.
Key Financial Metrics and Transaction Details
Transaction Overview:
- Existing Warrants Exercised: 1,963,637 ADSs (comprising 1,363,637 from Jan 2023 Series A and 600,000 from Dec 2021).
- Reduced Exercise Price: $1.53 per ADS (reduced from original prices of $6.00 and $5.50).
- Expected Gross Proceeds: Approximately $3.0 million.
- New Warrants Issued: 3,927,274 ADSs at an exercise price of $1.75 per ADS.
- Placement Agent Fees: 7.0% cash fee, 1.0% management fee, plus $50,000 for expenses and $15,950 for clearing fees.
- Placement Agent Warrants: 137,455 ADSs at an exercise price of $1.9125 per ADS.
Financial Statements: This filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a specific capital transaction.
Material Changes and Use of Proceeds
Capital Structure Changes:
- Significant reduction in exercise prices for existing warrants held by the specific Holder.
- Extension of the term for certain Series B warrants to twenty months from the Closing Date.
- Issuance of new warrants representing potential dilution of 3,927,274 ADSs.
Use of Proceeds: Net proceeds are expected to be used for funding research and development, clinical trials, and general working capital.
Guidance, Risks, and Contingencies
Closing Conditions: The transaction is expected to close on or about November 24, 2023, subject to customary closing conditions. Failure to satisfy these conditions may prevent the closing.
Lock-Up and Restrictions:
- The Company agreed not to issue any ADSs, ordinary shares, or equivalents for 60 days after the Closing Date (subject to exceptions).
- The Company agreed not to effect any Variable Rate Transaction for one year after the Closing Date.
- Resale of New Warrant Shares requires a registration statement to be filed and declared effective within 90 days.
Liquidity Risk: There is no established trading market for the New Warrants, and the Company does not expect an active market to develop, resulting in extremely limited liquidity for these instruments.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $3.0 million gross proceeds receipt.
- Review the impact of the 3,927,274 new warrants on fully diluted share count and potential dilution.
- Confirm the filing and effectiveness of the Form F-3 resale registration statement for the New Warrant Shares.
- Monitor the Company's cash burn rate to assess if the $3.0 million net proceeds are sufficient for stated R&D and clinical trial needs.
- Check for any subsequent filings regarding the 60-day lock-up period on new issuances.